Integration of CRISPR-Cas9 Screens and Multi-Omics Profiling Reveals CHD7-ANGPT1 as a Novel Multi-Drug Resistance Axis in AML [ATAC-seq]

To explore how the loss of function of CHD7 leads to drug resistance in acute myeloid leukemia (AML) cells, we investigated the transcriptional programs regulated by CHD7 in OCI-AML2 cells under different drug treatment conditions. This study aims to uncover the role of CHD7 in drug sensitivity and resistance, providing a theoretical basis for developing new therapeutic strategies. Assessment of gene expression changes in CHD7 knockdown and control sgSC cells under three different conditions:DMSO,Gilteritinib,Venetoclax.

为探究CHD7功能缺失如何引发急性髓系白血病（acute myeloid leukemia, AML）细胞的耐药性，本研究针对不同药物处理条件下的OCI-AML2细胞，分析了CHD7所调控的转录程序。本研究旨在阐明CHD7在药物敏感性与耐药性中的作用，为新型治疗策略的开发提供理论依据。本研究对三种不同处理条件：二甲基亚砜（DMSO）、吉列替尼（Gilteritinib）、维奈克拉（Venetoclax）下的CHD7敲低细胞与对照sgSC细胞的基因表达变化进行了评估。